![Belgium Secures Group G Top Spot with Dominant Win Over New Zealand, Sets Stage for Potential USMNT Showdown]](https://i3.wp.com/sportshub.cbsistatic.com/i/r/2026/06/27/0e9c2a4a-e12b-48ca-bd4d-36df7d98a327/thumbnail/1200x675/a6ee943d2caf047da5e3c420db0ed763/kdb-pulisic.jpg?w=1024&resize=1024,1024&ssl=1 "Belgium Secures Group G Top Spot with Dominant Win Over New Zealand, Sets Stage for Potential USMNT Showdown]")
RTTNews — Larimar Therapeutics, Inc. (LRMR) will host an investor event on Monday, June 29, 2026, at 7:45 a.m. ET to provide updates on its Nomlabofusp program for Friedreich’s ataxia.
Friedreich’s ataxia is a progressive, inherited neurodegenerative disorder that impairs coordination, mobility, and overall quality of life. Larimar’s lead compound, Nomlabofusp, is being developed as a potential therapy for both adults and children with the disease.
During the webcast, the company will share a regulatory update and data from the ongoing Phase 2 long‑term open‑label study of Nomlabofusp. Larimar also plans to leverage its intracellular delivery platform to design fusion proteins targeting other rare diseases characterized by deficiencies in intracellular bioactive compounds.
LRMR has traded between $2.71 and $6.42 over the past year. The stock closed Friday at $3.66, up 4.57 %. In after‑hours trading, the stock is at $4.00, up 9.29 %.
